North China Pharmaceutical Group: Subsidiary Huasheng Awarded CEP Certification for Polymyxin B Sulfate API

3 day ago / Read about 0 minute

Author：小编

Huasheng, a wholly-owned subsidiary of the North China Pharmaceutical Group, has successfully secured the European Pharmacopoeia Certificate of Suitability (CEP) for its Polymyxin B Sulfate Chemical Active Pharmaceutical Ingredient (API). This prestigious certification, granted by the European Directorate for the Quality of Medicines & HealthCare, underscores the API's compliance with the stringent quality standards of the European Union's regulated market, thereby paving the way for its sale in the European market. Notably, Huasheng is one of only three domestic manufacturers of Polymyxin B Sulfate API to achieve this milestone, reflecting its commitment to excellence in research and development. The total investment in R&D for this drug amounts to 10.99 million yuan.

Previous page：Haihuan Technology Secures Hundreds of Millions in...

Next page：Sanyou Medical's JAZZSystem Receives Medical Devic...

Return to List

Hot Reading

2 day ago

Intel reportedly prepping supercharged Nova Lake-AX mobile chips for gaming

2 day ago

Corporate inadequacy has rendered my favorite rediscovered gadget useless

2 day ago

Firefox dev says Intel Raptor Lake crashes are increasing with rising temperatures in record European heat wave

2 day ago

iOS 26 Public Beta Launching Next Week, Says Rumors—When Exactly Will It Be?